Items Tagged ‘Erwinaze’

February 18th, 2015

Intravenous Administration of Erwinaze® Approved by FDA

By

The U.S. Food and Drug Administration (FDA) recently approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi).  Erwinaze is utilized as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.1 Administration of Erwinaze through an intravenous infusion provides patients with hypersensitivity […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, asparaginase, asparaginase Erwinia chrysanthemi, Erwinaze, FDA approval, Leukemia, leukemia treatment, News